Hamlet BioPharma Featured in Two Business Publications

Hamlet BioPharma, a pharmaceutical company developing new therapies against cancer and infections, has been featured in two prominent business publications: CEO World Magazine and the business news website Pulse 2.0. These features highlight the company's recent clinical trials and strategic growth.

CEO World Magazine, known for its focus on C-suite executives, included a spotlight on Hamlet BioPharma, featuring an interview with Chairman Professor Catharina Svanborg. The publication emphasized the company's advancements in treatments for cancer, tuberculosis, and other infections, as well as its approach combining research with business strategy. CEO World Magazine reaches a global audience of an estimated 12.4 million executives and decision-makers.

In addition, Pulse 2.0, which specializes in business and tech industry news, profiled Hamlet BioPharma. This feature discussed the company's ongoing clinical trials and the recent strategic merger between Hamlet Pharma and Selectimmune Pharma. Pulse 2.0 often profiles companies and leaders driving innovation and growth in technology and business.

Hamlet BioPharma focuses on developing new therapies for unmet needs in cancer and infectious diseases. The company's project portfolio includes potential treatments for conditions such as prostate cancer targeting the PSA protein and tuberculosis. These publications aim to increase visibility for the company's efforts in advancing medical research and clinical adoption.